Eli Lilly and Company: The Floodgates To Growth Keep Opening, A Big Win In China
Summary: Eli Lilly’s stock has surged 88.5% in the past year, driven by weight loss
Summary: Eli Lilly’s stock has surged 88.5% in the past year, driven by weight loss
Summary: Eli Lilly will acquire Morphic Holding for $3.2 billion, and the deal brings a
Summary: Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is
Summary: Eli Lilly’s new Alzheimer’s drug, Kisunla, shows promise with its unique treatment regimen and
Summary: Despite high market multiples, the Eli Lilly stock has outperformed the S&P 500 Health
Summary: Follow along as we discuss a potential top formation in Lilly’s stock price and
Summary: In recent months, Eli Lilly has continued to delight investors with growth in its
Summary: An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company’s donanemab
Summary: Eli Lilly and Company has gained approval on yet another prospective blockbuster drug, Donanemab,
Summary: Eli Lilly’s stock has seen significant gains due to the success of its GLP-1